A ramdomized phase II study of docetaxel alone or in combination with PANVAC™-V (Vaccinia) and PANVAC™-F (Fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229)

Clinical Breast Cancer

Volumn 7, Issue 2, 2006, Pages 176-179

  Arlen, Philip M ^a   Pazdur, Mary ^a   Skarupa, Lisa ^a   Rauckhorst, Myrna ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Randomized trials; Vaccine therapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DOCETAXEL; FOWLPOX VIRUS VACCINE; MUCIN 1; PANVAC F; PANVAC V; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; TAXOID;

ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SELF ADMINISTRATION; DRUG TARGETING; FOLLOW UP; FOWLPOX VIRUS; HUMAN; KAPLAN MEIER METHOD; MAMMOGRAPHY; METASTASIS POTENTIAL; PATIENT EDUCATION; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT PLANNING; VACCINIA VIRUS; BREAST TUMOR; FEMALE; IMMUNOLOGY; METASTASIS; METHODOLOGY; PATHOLOGY; POXVIRUS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; NEOPLASM METASTASIS; POXVIRIDAE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TAXOIDS;

EID: 33745899583     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.032     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Hodge JW. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996; 43:127-134.
3. Foon KA, Chakraborty M, John WJ, et al. Immune-response to the carcinoembryonic antigen in patients treated with an antiidiotype antibody vaccine. J Clin Invest 1995; 96:334-342.
4. Fong L, Hou YF, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001; 98:8809-8814.
5. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999; 17:332-337.
6. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964-3973.
7. Marshall JL, Gulley JL, Arlen PM, et al. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7.1/ICAM-1/LFA-3) alone and sequentially with vaccinia-CEA (6D)-TRICOM with and without GM-CSF in patients with CEA-expressing carcinomas. J Clin Oncol 2005; 23:720-731.
8. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Chin Cancer Res 2001; 7:1181-1191.
9. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular-cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265:15286-15293.
10. Hadden JW. The immunology and immunotherapy of breast cancer: an update. Int J Immunopharmacol 1999; 2:79-101.
11. Aoki R, Tanaka S, Haruma K, et al. MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma. Dis Colon Rectum 1998; 41:1262-1272.
12. Hiraga Y, Tanaka S, Haruma K, et al. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55:307-319.
13. Zotter S, Hageman P, Lossnitzer A, et al. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988; 11:55-101.
14. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997; 47:813-830.
15. Ramanathan R, Lee K, McKolanis J, et al. Phase 1 study of a MUC-1 synthetic vaccine admixed with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19:457a (Abstract #1791).
16. Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000; 23:570-580.
17. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004; 15:1358-1365.
18. Maas IW, Boven E, Pinedo HM, et al. The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int J Cancer 1991; 48:749-756.
19. Abdalla EE, Blair GE, Jones RA, et al. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 1995; 87:489-496.
20. Aquino A, Prete SP, Greiner JW, et al. Effect of the combined treatment of 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 1998; 4:2473-2481.
21. Mizutani Y, Wu XX, Yoshida O, et al. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-flourouracil. Oncol Rep 1999; 6:979-982.
22. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cells enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001; 50:445-455.
23. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-2671.
24. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
25. Carson WE III, Shapiro CL, Crespin TR, et al. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 2004; 10:3401-3409.
26. Arlen P, Gulley J, Parker C, et al. A pilot study of concurrent docetaxel plus PSA pox-vaccine versus vaccine alone in metastatic androgen independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 2003; 22:423a (Abstract #1701).